JP2009541571A - 親水性ポリウレタン化合物 - Google Patents
親水性ポリウレタン化合物 Download PDFInfo
- Publication number
- JP2009541571A JP2009541571A JP2009517393A JP2009517393A JP2009541571A JP 2009541571 A JP2009541571 A JP 2009541571A JP 2009517393 A JP2009517393 A JP 2009517393A JP 2009517393 A JP2009517393 A JP 2009517393A JP 2009541571 A JP2009541571 A JP 2009541571A
- Authority
- JP
- Japan
- Prior art keywords
- linear polymer
- polymer
- polymer according
- diisocyanate
- diol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004814 polyurethane Substances 0.000 title description 17
- 229920002635 polyurethane Polymers 0.000 title description 17
- 150000001875 compounds Chemical class 0.000 title description 7
- 229920000642 polymer Polymers 0.000 claims abstract description 103
- 239000013543 active substance Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 12
- 239000012948 isocyanate Substances 0.000 claims abstract description 10
- 150000002513 isocyanates Chemical class 0.000 claims abstract description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000013270 controlled release Methods 0.000 claims abstract description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- 239000002202 Polyethylene glycol Substances 0.000 claims description 24
- 150000002009 diols Chemical class 0.000 claims description 16
- 125000005442 diisocyanate group Chemical group 0.000 claims description 12
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- GHLKSLMMWAKNBM-UHFFFAOYSA-N dodecane-1,12-diol Chemical compound OCCCCCCCCCCCCO GHLKSLMMWAKNBM-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229940008841 1,6-hexamethylene diisocyanate Drugs 0.000 claims description 4
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- GJBXIPOYHVMPQJ-UHFFFAOYSA-N hexadecane-1,16-diol Chemical compound OCCCCCCCCCCCCCCCCO GJBXIPOYHVMPQJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 3
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 claims description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 230000008961 swelling Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 238000006116 polymerization reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 230000001588 bifunctional effect Effects 0.000 description 9
- -1 (monolithic devices) Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 8
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 7
- 229960004884 fluconazole Drugs 0.000 description 7
- 239000000017 hydrogel Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 6
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- INSRQEMEVAMETL-UHFFFAOYSA-N decane-1,1-diol Chemical compound CCCCCCCCCC(O)O INSRQEMEVAMETL-UHFFFAOYSA-N 0.000 description 4
- 239000012973 diazabicyclooctane Substances 0.000 description 4
- GTZOYNFRVVHLDZ-UHFFFAOYSA-N dodecane-1,1-diol Chemical compound CCCCCCCCCCCC(O)O GTZOYNFRVVHLDZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000000748 compression moulding Methods 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000010128 melt processing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000010094 polymer processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 238000007551 Shore hardness test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- LGDAGYXJBDILKZ-UHFFFAOYSA-N [2-methyl-1,1-dioxo-3-(pyridin-2-ylcarbamoyl)-1$l^{6},2-benzothiazin-4-yl] 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LGDAGYXJBDILKZ-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- JQZRVMZHTADUSY-UHFFFAOYSA-L di(octanoyloxy)tin Chemical compound [Sn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O JQZRVMZHTADUSY-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000000709 neurohypophysis hormone Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068189 posterior pituitary hormone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002868 serotonin 5-HT1 receptor antagonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- OGFYIDCVDSATDC-UHFFFAOYSA-N silver silver Chemical compound [Ag].[Ag] OGFYIDCVDSATDC-UHFFFAOYSA-N 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/20—Heterocyclic amines; Salts thereof
- C08G18/2045—Heterocyclic amines; Salts thereof containing condensed heterocyclic rings
- C08G18/2063—Heterocyclic amines; Salts thereof containing condensed heterocyclic rings having two nitrogen atoms in the condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4833—Polyethers containing oxyethylene units
- C08G18/4837—Polyethers containing oxyethylene units and other oxyalkylene units
- C08G18/4841—Polyethers containing oxyethylene units and other oxyalkylene units containing oxyethylene end groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/75—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
- C08G18/758—Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic containing two or more cycloaliphatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Polyurethanes Or Polyureas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
特に、本発明は、
(a)数平均分子量が4000未満のポリエチレンオキシド、
(b)脂肪族ジオール、
(c)二官能性イソシアネート
を共に反応させることにより得られる水膨潤性線状ポリマーを提供する。
種々のポリエチレングリコール、ジオール、ジイソシアネートを理論混合比の範囲で用い、製造される親水性線状ポリウレタンポリマーに関する効果を検証した。PEG400、PEG600、PEG1000、PEG1200、PEG2000、PEG4000は、それぞれ分子量400、600、1000、1200、2000、及び4000g/molのポリエチレングリコールである。DDは1,10−デカンジオール、DDDは1,12−ドデカンジオール、DMDIはジシクロヘキシルメタン−4,4−ジイソシアネート、HMDIは1,6−ヘキサメチレン−ジイソシアネート、FECl3は塩化第二鉄、DABCOはトリエチレンジアミン、SnOct2はオクタン酸第一錫である。
重合時間が製造されるポリマーに及ぼす効果を、トリプル検出SEC(triple detection size exclution chromatography)で調査した。ポリマーAについて、重合時間に応じた分子量を測定した。結果を図1に示す。ポリマーの分子量は、レオロジー(rheology)、溶融流れ(melt flow)、及び力学的特性を決定するものであるので、分子量測定が重要であることは明らかである。
実施例1において重合触媒は塩化第二鉄を用いたが、ポリマーPではDABCOとSnOct2、ポリマーOではDABCOが用いられ、ポリマーDでは触媒なしで重合が行われた(表1参照)。
ジシクロヘキシルメタン−4,4−ジイソシアネート(DMDI)の代わりに、ポリマーC、D、F、H、I、J、K、L、M、O、及びPでは1,6−ヘキサメチレン−ジイソシアネート(HMDI)を用いて実施例1と同様に重合を行なった(表1参照)。
表1のポリマーHでは二段階重合法を用いた。重合反応前にポリエチレングリコール(PEG)と触媒の混合物をロータリーエバポレーターで乾燥した。ジイソシアネート(HMDI)をまず95℃に加熱した撹拌反応槽に供給し、その後溶融したPEG触媒混合物を一定の速度で混合(60rpm)しながら12分以内で添加した。28分間反応を続けた時点で、ジオール(DDD)を反応器に供給した。反応混合物をさらに7分間撹拌した後混合を終了し、ポリマーを95℃で10時間かけて硬化させた後室温まで冷却した。
表1に記載したポリマーについて適当な溶媒を見付けるために、異なる溶媒に溶解した。溶解度試験は、室温(RT)または温度を上げて24時間実施した。選択したポリマーの溶解度の結果を表2に示す。表中、YESは溶解した場合、NOは溶解しない場合、ゲルはゲル化した場合、−は測定していないことを示す。
選択したポリマーについて、水、エタノール、イソプロピルアルコール(IPA)、及びIPAと水の50%混合物中で、ポリマーに吸収される溶媒の量を測定する膨潤測定を行なった。5〜10の試料の膨潤の平均値として算出した結果を表3に示す。算出に使用した式は下記の通りである。
膨潤率(%)={(膨潤重量−乾燥重量)/乾燥重量}×100
製造したポリマーのショア硬度をタイプAとタイプDのデュロメータ(Durometer)を用い測定した。これらの測定は当業者によく知られている。4回の測定値の平均値とした結果を表4に示す。
表1から選択したポリマー及び薬物担持ポリマー製剤を加工前に真空下で一晩乾燥した。圧縮成形機の上部板と下部板の温度を目的の加工温度に設定した。型と熱した板の間に二枚のテフロン(登録商標)シートを配置した。3〜5分間溶融した後、170〜200barsの加圧下に30〜120秒間保持した。所定量のポリマーを型に満たした。室温まで冷却した後、試料(大きさ30mm×10mm×1mmのペッサリー)を機械的に型抜きし、分析用として冷凍庫に保存した。フィルム加工条件を表5に示す。
モデル薬物であるフルコナゾール(fluconazole)を、選択したポリマーに担持した。実験用16mm同方向回転二軸押出機によりポリマーに担持した。薬物担持条件を表6に示す。
押出担持ポリマーから放出したフルコナゾールの量を米国薬局方(USP)のパドル法に基づく溶出試験により検討した。この技術は、Distek社の溶出試験機(型番;model 2100C)(回転速度50rpmのパドル)が蠕動ポンプ(Icalis peristaltic pump)を介して分光光度計(Unicam UV500)に接続している自動UV(紫外)溶出システムで構成される。このシステムをDsolve(ソフトウエア)を用いて操作した。実験条件は温度:37℃、溶出液:脱イオン化し脱気した水500ml。
Claims (16)
- (a)数平均分子量が4000未満のポリエチレンオキシド、
(b)脂肪族ジオール、
(c)二官能性イソシアネート
を共に反応して得られることを特徴とする水膨潤性線状ポリマー。 - ポリエチレンオキシドが、当量200〜4000g/molのジオールである請求項1に記載の線状ポリマー。
- 脂肪族ジオールが、炭素数5〜20のジオールである先行するいずれかの請求項に記載の線状ポリマー。
- 脂肪族ジオールが、炭素数8〜15のジオールである請求項3に記載の線状ポリマー。
- 脂肪族ジオールが、1,6−へキサンジオール、1,10−デカンジオール、1,12−ドデカンジオールまたは1,16−ヘキサデカンジオールである請求項4に記載の線状ポリマー。
- 二官能性イソシアネートが、ジシクロヘキシルメタン−4,4−ジイソシアネート、ジフェニルメタン−4,4−ジイソシアネートまたは1,6−へキサメチレンジイソシアネートである先行するいずれかの請求項に記載の線状ポリマー。
- (a):(b):(c)の組成比が、当量換算で0.01〜0.1:1:1.01〜1.1の範囲内である先行するいずれかの請求項に記載の線状ポリマー。
- 親水性ポリエチレングリコール(PEG)単位の含有量が、ポリマーの50重量%未満である先行するいずれかの請求項に記載の線状ポリマー。
- 疎水性ポリエチレングリコール(PEG)単位の含有量が、ポリマーの20重量%を超える先行するいずれかの請求項に記載の線状ポリマー。
- ジイソシアネートの含有量が、ポリマーの20〜50重量%である先行するいずれかの請求項に記載の線状ポリマー。
- ポリエチレンオキシドを、脂肪族ジオールと共に真空下85〜100℃で、溶解、乾燥することを特徴とする先行するいずれかの請求項に記載の水膨潤性線状ポリマーの製造方法。
- 請求項1〜10に記載の水膨潤性線状ポリマーと活性剤とからなることを特徴とする放出制御組成物。
- 固形製剤に加工された請求項12に記載の組成物。
- 固形製剤が、座剤、膣リングもしくはペッサリー、口腔挿入剤、または経皮吸収型パッチである請求項13に記載の組成物。
- 固形製剤が、インプラントである請求項13に記載の組成物。
- 活性剤が、分子量200〜20,000の薬学的活性剤である請求項12〜15のいずれかに記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0613333.4 | 2006-07-05 | ||
GBGB0613333.4A GB0613333D0 (en) | 2006-07-05 | 2006-07-05 | Hydrophilic polyurethane compositions |
PCT/GB2007/002401 WO2008003932A1 (en) | 2006-07-05 | 2007-06-27 | Hydrophilic polyurethane compositions |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009541571A true JP2009541571A (ja) | 2009-11-26 |
JP2009541571A5 JP2009541571A5 (ja) | 2010-08-05 |
JP5394237B2 JP5394237B2 (ja) | 2014-01-22 |
Family
ID=36926482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009517393A Active JP5394237B2 (ja) | 2006-07-05 | 2007-06-27 | 親水性ポリウレタン化合物 |
Country Status (13)
Country | Link |
---|---|
US (2) | US8974813B2 (ja) |
EP (2) | EP2966104B1 (ja) |
JP (1) | JP5394237B2 (ja) |
CN (1) | CN101484493B (ja) |
AU (1) | AU2007271000B2 (ja) |
BR (1) | BRPI0713630B1 (ja) |
CA (1) | CA2656489C (ja) |
ES (2) | ES2707749T3 (ja) |
GB (1) | GB0613333D0 (ja) |
HK (1) | HK1220220A1 (ja) |
PL (1) | PL2966104T3 (ja) |
TR (1) | TR201900597T4 (ja) |
WO (1) | WO2008003932A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019111839A1 (ja) * | 2017-12-04 | 2019-06-13 | 住友精化株式会社 | 揮発性物質放散用組成物 |
JP2022500394A (ja) * | 2018-09-17 | 2022-01-04 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | ポリウレタン賦形剤 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
KR20100120665A (ko) | 2008-01-25 | 2010-11-16 | 더 유니버시티 오브 유타 리서치 파운데이션 | 일차 방출 중합체 |
WO2010141729A1 (en) | 2009-06-03 | 2010-12-09 | Forsight Labs, Llc | Anterior segment drug delivery |
US8393979B2 (en) | 2010-06-24 | 2013-03-12 | Nike, Inc. | Golf ball with hydrophilic coating layer |
US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
US8602915B2 (en) | 2010-11-01 | 2013-12-10 | Nike, Inc. | Golf ball with changeable dimples |
WO2012158779A1 (en) | 2011-05-17 | 2012-11-22 | Reprotect, Inc. | Reusable intravaginal delivery device, system, and method |
EP2755615B1 (en) | 2011-09-14 | 2022-04-06 | Forsight Vision5, Inc. | Ocular insert apparatus |
DK2911623T3 (da) | 2012-10-26 | 2019-10-28 | Forsight Vision5 Inc | Oftalmisk system til langvarig frigivelse af lægemiddel til øjet |
US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
US20160311964A1 (en) * | 2013-12-10 | 2016-10-27 | Lubrizol Advanced Materials, Inc. | Highly resilient thermoplastic polyurethanes |
US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
CN108283726A (zh) * | 2018-03-05 | 2018-07-17 | 湖南科技大学 | 一种聚氨酯基创伤敷料的制备方法 |
CN108404192A (zh) * | 2018-03-05 | 2018-08-17 | 湖南科技大学 | 一种止血创伤敷料的制备方法 |
CN114096290A (zh) * | 2019-06-28 | 2022-02-25 | 尤达莫恩科技私人有限公司 | 模制聚氨酯水凝胶 |
GB201916808D0 (en) | 2019-11-19 | 2020-01-01 | Ferring Bv | Pharmaceutical delivery device |
FR3116715A1 (fr) * | 2020-11-30 | 2022-06-03 | Polymerexpert Sa | Polymère apte à former un revêtement glissant pour injecteur ophtalmique |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753663A (ja) * | 1993-07-30 | 1995-02-28 | Takiron Co Ltd | 経皮吸収製剤用基剤ポリマー |
JPH09157409A (ja) * | 1995-12-01 | 1997-06-17 | Nippon Miractran Kk | 透湿フィルム又はシート、及びその製造方法 |
JP2001501232A (ja) * | 1996-09-20 | 2001-01-30 | バイエル・アクチエンゲゼルシヤフト | 活性物質含有の熱可塑性ポリウレタン |
JP2002088571A (ja) * | 2000-09-11 | 2002-03-27 | Du Pont Toray Co Ltd | ポリウレタン繊維の製造方法 |
JP2002361053A (ja) * | 2001-06-12 | 2002-12-17 | Nisshinbo Ind Inc | 分離膜モジュールの洗浄用ゲル粒子、製法及び洗浄方法 |
JP2006500456A (ja) * | 2002-09-27 | 2006-01-05 | コントロールド・セラピューティクス(スコットランド)・リミテッド | 水膨潤性ポリマー |
Family Cites Families (354)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE505703C2 (sv) | 1995-12-15 | 1997-09-29 | Polyrand Ab | Linjär blockpolymer innefattande urea- och uretangrupper, förfarande för framställning av linjära blockpolymerer samt användning av blockpolymererna som implantat |
US3916898A (en) | 1964-05-20 | 1975-11-04 | Searle & Co | Administration of medicaments and the like |
US3487068A (en) | 1966-12-16 | 1969-12-30 | Upjohn Co | Lincomycin-2-phosphates,7-substituted compounds and salts thereof |
US3860701A (en) * | 1968-04-22 | 1975-01-14 | Searle & Co | Method for use and compositions of 11-lower alkyl steroids and drug delivery system for the controlled elution of 11-lower alkyl steroids |
US3830907A (en) * | 1968-04-22 | 1974-08-20 | Searle & Co | Compositions for the sustained release of 17alpha-ethyl-19-nortestosterone |
US3565991A (en) * | 1968-04-22 | 1971-02-23 | Searle & Co | Methods for use and compositions of 17alpha-ethyl-19-nortestosterone and carriers for the sustained release of steroids |
US3639157A (en) * | 1968-07-18 | 1972-02-01 | Bayer Ag | Process for finishing textile materials with a polymer of a vinyl compound and the reaction product of a polyol and an organic polyisocyanate |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3896819A (en) * | 1969-04-01 | 1975-07-29 | Alejandro Zaffaroni | IUD having a replenishing drug reservoir |
US3948262A (en) * | 1969-04-01 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3967618A (en) * | 1969-04-01 | 1976-07-06 | Alza Corporation | Drug delivery device |
US3734097A (en) * | 1969-04-01 | 1973-05-22 | Alza Corp | Therapeutic adhesive tape |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3845761A (en) | 1970-06-02 | 1974-11-05 | Alza Corp | Intrauterine contraceptive anti-fertility device for the management of reproduction |
US3737521A (en) * | 1970-12-09 | 1973-06-05 | Goodrich Co B F | Formulation for sustained release of a biological agent |
US4034756A (en) * | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3760805A (en) | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
US3941880A (en) * | 1971-02-22 | 1976-03-02 | G. D. Searle & Co. | Method for use of 11-lower alkyl steroids |
US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3881043A (en) | 1971-06-21 | 1975-04-29 | Ppg Industries Inc | Laminated safety windshields |
US4041208A (en) | 1971-06-21 | 1977-08-09 | Ppg Industries, Inc. | Transparent, impact-resistant polyesterurethane laminates |
US3931113A (en) | 1971-06-21 | 1976-01-06 | Ppg Industries, Inc. | Impact-resistant thermoplastic polyester urethanes |
US3892842A (en) * | 1971-09-01 | 1975-07-01 | Alza Corp | Intrauterine contraceptive device for releasing steroid having double bond functionality |
US3948254A (en) * | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3867933A (en) * | 1973-03-06 | 1975-02-25 | Tecna Corp | Intrauterine device and process of making the same |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4036227A (en) * | 1973-04-25 | 1977-07-19 | Alza Corporation | Osmotic releasing device having a plurality of release rate patterns |
FR2250520B1 (ja) * | 1973-11-09 | 1977-04-15 | Cournut Rene | |
US3901852A (en) * | 1974-07-29 | 1975-08-26 | Upjohn Co | Thermoplastic polyurethanes prepared from 4,4'-methylenebis (phenyl isocyanate) |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4135514A (en) * | 1974-12-23 | 1979-01-23 | Alza Corporation | Osmotic releasing system for administering ophthalmic drug to eye of animal |
US4018918A (en) | 1975-05-20 | 1977-04-19 | The Upjohn Company | Topical clindamycin preparations |
GB1479987A (en) | 1975-06-20 | 1977-07-13 | Interox Chemicals Ltd | Polyurethanes |
US4036360A (en) | 1975-11-12 | 1977-07-19 | Graham Magnetics Incorporated | Package having dessicant composition |
GB1551620A (en) | 1976-12-13 | 1979-08-30 | Ici Ltd | Delivery means for biologically active agents |
US4235988A (en) * | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
US4289757A (en) | 1978-02-28 | 1981-09-15 | The Upjohn Company | Method for treating inflammation |
US4205115A (en) | 1978-04-19 | 1980-05-27 | Ppg Industries, Inc. | Polyester coating composition |
US4215691A (en) * | 1978-10-11 | 1980-08-05 | Alza Corporation | Vaginal contraceptive system made from block copolymer |
US4286587A (en) | 1978-10-11 | 1981-09-01 | Alza Corporation | Vaginal drug delivery system made from polymer |
US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
US5017382A (en) | 1979-03-21 | 1991-05-21 | National Research Development Corporation | Controlled release compositions (II) |
US5079009A (en) | 1979-03-21 | 1992-01-07 | National Research Development Corporation | Controlled release compositions including polyethylene oxide with urethane cross-linking |
EP0016654B1 (en) | 1979-03-21 | 1985-09-11 | National Research Development Corporation | Composition for the controlled release of a prostaglandine and process for its preparation |
US4250611A (en) * | 1979-04-19 | 1981-02-17 | Alza Corporation | Process for making drug delivery device with reservoir |
JPS56253A (en) | 1979-06-11 | 1981-01-06 | Sumitomo Metal Ind Ltd | Cr-mo steel of excellent strength and tenacity to be hot- worked |
US4264757A (en) | 1979-06-26 | 1981-04-28 | Union Carbide Corporation | Radiation-curable allyl- or vinyl capped polycaprolactone compositions |
US4402695A (en) | 1980-01-21 | 1983-09-06 | Alza Corporation | Device for delivering agent in vagina |
US4731289A (en) | 1980-02-14 | 1988-03-15 | Ppg Industries, Inc. | Abrasion resistant polyurethane coatings for rigid plastics |
US4276405A (en) | 1980-03-28 | 1981-06-30 | Union Carbide Corporation | Low-energy-curable coatings compositions |
DE3017989C2 (de) * | 1980-05-10 | 1982-05-19 | IPOS Gesellschaft für integrierte Prothesen-Entwicklung und orthopädietechnischen Service mbH & Co KG, 2120 Lüneburg | "Auffangbeutel für künstliche Darmausgänge" |
US4466936A (en) * | 1981-02-03 | 1984-08-21 | Bayer Aktiengesellschaft | Production of molds using gel compositions with depot action based on a polyurethane matrix and relatively high molecular weight polyols |
AU558611B2 (en) | 1981-02-03 | 1987-02-05 | Bayer Aktiengesellschaft | Polyurethane gel |
JPS57155230A (en) | 1981-02-27 | 1982-09-25 | Daicel Chem Ind Ltd | Lactone polymer having narrow molecular weight distribution and its preparation |
JPS57185313A (en) | 1981-05-08 | 1982-11-15 | Daicel Chem Ind Ltd | Polyurethane and its preparation |
US4426485A (en) | 1982-06-14 | 1984-01-17 | Union Carbide Corporation | Polymers with hydrophobe bunches |
JPS5948409A (ja) | 1982-09-10 | 1984-03-19 | Teikoku Seiyaku Kk | 矯正的歯牙移動促進剤 |
US4438225A (en) | 1983-04-12 | 1984-03-20 | Henkel Corporation | Polyester polyols from bishydroxymethyl tricyclo compounds and caprolactone and polyurethanes based thereon |
GB8319766D0 (en) | 1983-07-22 | 1983-08-24 | Graham N B | Controlled release device |
FR2557576B1 (fr) | 1984-01-03 | 1988-06-03 | Gould Francis | Composition d'acrylate de polyurethane hydrophile, son procede de preparation et son utilisation comme pansement pour brulures, implant, contraceptif, dispositif intra-uterin, canule, systeme d'application orale, membrane permeable aux gaz, prothese de la cornee, pansement chirurgical, membrane de dialyse, lentille de contact et enrobage de coques de bateau |
US4694238A (en) | 1984-01-10 | 1987-09-15 | Peter Norton | Dual voltage power supply system for vehicles |
GB8403138D0 (en) | 1984-02-07 | 1984-03-14 | Graham N B | Sustained release of active ingredient |
US4503216A (en) | 1984-02-21 | 1985-03-05 | Eastman Kodak Company | Hydroxyl-terminated polyether-esters |
US4568741A (en) | 1984-05-15 | 1986-02-04 | The Upjohn Company | Synthesis of 7-halo-7-deoxylincomycins |
US4596576A (en) * | 1984-10-12 | 1986-06-24 | Akzo N.V. | Release system for two or more active substances |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS61250019A (ja) | 1985-04-27 | 1986-11-07 | Bridgestone Corp | 微小気泡質状ポリウレタンエラストマ−の製造方法 |
JPS6257467A (ja) | 1985-09-06 | 1987-03-13 | Asahi Glass Co Ltd | コ−テイング剤組成物 |
US4707495A (en) | 1985-10-28 | 1987-11-17 | Ortho Pharmaceutical | Peptic ulcer treatment method |
US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4917686A (en) | 1985-12-16 | 1990-04-17 | Colorado Biomedical, Inc. | Antimicrobial device and method |
IE59361B1 (en) | 1986-01-24 | 1994-02-09 | Akzo Nv | Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension |
US5219885A (en) | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
US4804691A (en) | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
DE3882319T2 (de) | 1987-09-28 | 1994-02-17 | Kuraray Co | Lederartiges Schichtprodukt und Verfahren zu dessen Herstellung. |
US5035891A (en) * | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
JP2538953B2 (ja) | 1987-11-17 | 1996-10-02 | 三菱重工業株式会社 | 工業用ロボットのバランス機構 |
EP0400015A4 (en) | 1987-12-02 | 1991-01-16 | Tyndale Plains-Hunter, Ltd. | Hydrophilic polyurethanes of improved strength |
WO1989007117A1 (en) | 1988-02-01 | 1989-08-10 | Tyndale Plains-Hunter, Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
US5064653A (en) | 1988-03-29 | 1991-11-12 | Ferris Mfg. Co. | Hydrophilic foam compositions |
IE60383B1 (en) * | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
US5219663A (en) | 1988-06-22 | 1993-06-15 | Hitachi Maxell, Ltd. | Magnetic recording medium having a magnetic layer formed from an aromatic polycarbonate polyurethane resin |
JPH024736A (ja) | 1988-06-22 | 1990-01-09 | Hitachi Maxell Ltd | ポリカーボネートポリオール、芳香族ポリカーボネートポリウレタン樹脂、コーティング材、キャストフィルム、磁気記録媒体 |
JP2613441B2 (ja) | 1988-07-18 | 1997-05-28 | トヨタ自動車株式会社 | 発泡ポリウレタンの製法 |
US5000955A (en) * | 1988-07-29 | 1991-03-19 | Tyndale Plains-Hunter Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
US4933418A (en) | 1988-08-10 | 1990-06-12 | Ormco Corporation | Stain-resistant orthodontic device |
US4895934A (en) | 1988-08-22 | 1990-01-23 | E. I. Du Pont De Nemours And Company | Process for the preparation of clindamycin phosphate |
SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
US5470829A (en) | 1988-11-17 | 1995-11-28 | Prisell; Per | Pharmaceutical preparation |
FR2641786B1 (fr) | 1989-01-19 | 1992-09-11 | Sami | Composition de polymere d'urethanne et preparation d'articles a partir de ces polymeres |
DE3903538A1 (de) | 1989-02-07 | 1990-08-16 | Basf Ag | Herstellung von emulgatorfreien, waessrigen polyurethandispersionen |
ES2010145A6 (es) * | 1989-03-02 | 1989-10-16 | Uriach & Cia Sa J | Procedimiento para la obtencion de derivados de la 2-picolilamina. |
US5888930A (en) * | 1989-03-27 | 1999-03-30 | Bend Research, Inc. | Asymmetric microporous beads for controlled release |
US5002540A (en) * | 1989-05-22 | 1991-03-26 | Warren Kirschbaum | Intravaginal device and method for delivering a medicament |
US5034461A (en) | 1989-06-07 | 1991-07-23 | Bausch & Lomb Incorporated | Novel prepolymers useful in biomedical devices |
US5061254A (en) | 1989-06-21 | 1991-10-29 | Becton, Dickinson And Company | Thermoplastic elastomeric hydrophilic polyetherurethane expandable catheter |
US5110598A (en) * | 1989-06-30 | 1992-05-05 | Smithkline Beecham Corp. | Intermittent release dosage form |
US5178874A (en) * | 1989-06-30 | 1993-01-12 | Smithkline Beechman Corporation | Intermittent release dosage form |
JP2844474B2 (ja) | 1989-07-19 | 1999-01-06 | ダイセル化学工業株式会社 | ポリウレタンの製造方法 |
GB8918589D0 (en) | 1989-08-15 | 1989-09-27 | Graham Neil B | Polymeric compositions |
US5118779A (en) * | 1989-10-10 | 1992-06-02 | Polymedica Industries, Inc. | Hydrophilic polyurethane elastomers |
AU636668B2 (en) | 1989-10-18 | 1993-05-06 | Ferris Corp. | Process for preparing a sheet of polymer-based foam |
DE4006521A1 (de) | 1990-03-02 | 1991-09-05 | Bayer Ag | Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen |
KR910019750A (ko) | 1990-05-09 | 1991-12-19 | 피터 클로렌 2세 | 압출장치 |
DE4019171A1 (de) | 1990-06-15 | 1991-12-19 | Henkel Kgaa | Beschichtungsmittel |
GB2244920B (en) | 1990-06-16 | 1994-05-25 | British Aerospace | A contraceptive device |
US5130126A (en) | 1990-07-09 | 1992-07-14 | Nippon Oil & Fats Co., Ltd. | Polymer-drug conjugate and a method of producing it |
DK0540580T3 (da) | 1990-07-26 | 1994-05-16 | Monsanto Co | Polymert lægemiddelafgivelsessystem |
US5326632A (en) | 1990-08-07 | 1994-07-05 | Komatsu Seiren Co., Ltd. | Moisture-permeable waterproof fabric and process for production thereof |
US5114718A (en) * | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
JPH05239205A (ja) | 1991-02-13 | 1993-09-17 | Ajinomoto Co Inc | ポリアミノ酸ウレタン樹脂 |
GB2254002B (en) | 1991-01-16 | 1995-03-22 | Controlled Therapeutics | Retrievable pessary |
US5652274A (en) | 1991-03-01 | 1997-07-29 | Martin; Alain | Therapeutic-wound healing compositions and methods for preparing and using same |
US5159047A (en) | 1991-06-14 | 1992-10-27 | E. I. Du Pont De Nemours And Company | Coatings containing caprolactone oligomer polyols |
CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
US5176907A (en) * | 1991-08-13 | 1993-01-05 | The Johns Hopkins University School Of Medicine | Biocompatible and biodegradable poly (phosphoester-urethanes) |
US5322063A (en) | 1991-10-04 | 1994-06-21 | Eli Lilly And Company | Hydrophilic polyurethane membranes for electrochemical glucose sensors |
US5252602A (en) | 1991-10-11 | 1993-10-12 | Rafeul Alam | Effects of misoprostol on allergic responses |
HUT74560A (en) | 1991-10-16 | 1997-01-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
US6117843A (en) | 1992-02-18 | 2000-09-12 | Lloyd J. Baroody | Compositions for the treatment of acne containing clindamycin and benzoyl peroxide |
US5650171A (en) * | 1992-04-29 | 1997-07-22 | Penederm, Inc. | Retinoic acid-containing polyether-polyurethane compositions |
US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
JP3119533B2 (ja) | 1992-05-27 | 2000-12-25 | 日本ペイント株式会社 | 耐チッピング性塗料組成物 |
US5710215A (en) | 1992-06-15 | 1998-01-20 | Ebnother Ag | Method and material mixture for manufacture of reactive hotmelts |
JP2909477B2 (ja) | 1992-07-16 | 1999-06-23 | ビーティージー・インターナショナル・リミテッド | 回収可能なペッサリー |
DE4225045A1 (de) | 1992-07-29 | 1994-02-03 | Basf Ag | Verwendung von wasserlöslichen oder in Wasser dispergierbaren Polyurethanen als Hilfsmittel in kosmetischen und pharmazeutischen Zubereitungen und Polyurethane, die Polymilchsäurepolyole einpolymerisiert enthalten |
US5310759A (en) | 1992-08-12 | 1994-05-10 | Bockman Richard S | Methods of protecting and preserving connective and support tissues |
US6328991B1 (en) | 1992-10-21 | 2001-12-11 | John Myhling | Composition and method for prevention of sexually transmitted diseases, including aids |
ATE239431T1 (de) * | 1992-10-21 | 2003-05-15 | Gynetech Lab Inc | Abgabesystem bestehend aus einem vaginaschwamm |
US5747582A (en) | 1992-10-29 | 1998-05-05 | Bayer Aktiengesellschaft | Aqueous coating compositions and their use for the preparation of coatings that are permeable to water vapor |
DE4241118A1 (de) | 1992-12-07 | 1994-06-09 | Basf Ag | Verwendung von kationischen Polyurethanen und Polyharnstoffen als Hilfsmittel in kosmetischen und pharmazeutischen Zubereitungen |
DE4242687B8 (de) | 1992-12-17 | 2006-01-12 | Henkel Kgaa | Hydrophile Polyurethane |
DE4315173A1 (de) | 1992-12-23 | 1994-06-30 | Bayer Ag | Reine, insbesondere katalysatorfreie Polyurethane |
US5324746A (en) | 1993-02-12 | 1994-06-28 | Mckee Rex N | Method of treating damaged mucosal and epithelial tissues with misoprostol |
GB9306887D0 (en) | 1993-04-01 | 1993-05-26 | Graham Neil B | Random block copolymers |
US5328954A (en) | 1993-04-16 | 1994-07-12 | Icet, Inc. | Encrusting and bacterial resistant coatings for medical applications |
FR2705567A1 (fr) | 1993-05-25 | 1994-12-02 | Smith & Nephew Laboratoires Fi | Microparticules, procédé de préparation et application aux pansements. |
US5770650A (en) | 1995-10-06 | 1998-06-23 | Basf Corporation | Curable compositions for coatings |
US5994479A (en) | 1993-07-28 | 1999-11-30 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
US5792810A (en) | 1995-10-06 | 1998-08-11 | Basf Corporation | Curable coating composition including compound having carbamate and hydroxyl functionality |
US6423788B1 (en) | 1995-10-06 | 2002-07-23 | Basf Corporation | Curable coating composition |
EP0636670B1 (en) | 1993-07-28 | 1997-10-01 | Basf Corporation | Curable polyureas |
US6160058A (en) | 1993-07-28 | 2000-12-12 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
US5827930A (en) | 1995-10-06 | 1998-10-27 | Basf Corporation | Curable coating composition |
US5777048A (en) | 1996-06-20 | 1998-07-07 | Basf Corporation | Method for modified aminoplast compounds, aminoplasts obtained thereby and coatings containing the same |
US6084038A (en) | 1993-07-28 | 2000-07-04 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
US5854385A (en) | 1995-10-06 | 1998-12-29 | Basf Corporation | Coating compositions with low molecular weight carbamate or urea component |
US5744550A (en) | 1994-11-03 | 1998-04-28 | Basf Corporation | Curable coating compositions containing carbamate additives |
US5726244A (en) | 1995-08-10 | 1998-03-10 | Basf Corporation | Aqueous coating compositions for environmental etch resistant coatings |
US6080825A (en) | 1993-07-28 | 2000-06-27 | Basf Corporation | Curable coating compositions containing blends of carbamate-functional compounds |
US5514698A (en) | 1994-03-21 | 1996-05-07 | Ortho Pharmaceutical Corporation | Antifungal vaginal cream composition |
US5472785A (en) | 1994-04-12 | 1995-12-05 | Minnesota Mining And Manufacturing Company | Reactive wax-containing moisture curable hot melt composition |
US5985859A (en) | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
IL109539A0 (en) * | 1994-05-03 | 1994-08-26 | Yissum Res Dev Co | Substained-release pharmaceutical system for the delivery of antioxidants |
AU2613595A (en) | 1994-05-25 | 1995-12-18 | Henkel Kommanditgesellschaft Auf Aktien | Humidity-setting polyurethane hot-melt-type glue |
US5681278A (en) | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
WO1996006875A1 (en) | 1994-09-01 | 1996-03-07 | W.L. Gore & Associates, Inc. | Hydrophilic polyurethane |
GB9419566D0 (en) | 1994-09-27 | 1994-11-16 | El Refaey Hazem | Oral prostagladins for the routine management of the third stage of labour |
US5563233A (en) | 1994-11-16 | 1996-10-08 | Tyndale Plains-Hunter, Ltd. | Polyether polyurethane polymers and gels having improved absorption and slip properties |
IL116433A (en) * | 1994-12-19 | 2002-02-10 | Galen Chemicals Ltd | INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS |
US5659003A (en) | 1994-12-21 | 1997-08-19 | Basf Corporation | Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition |
AU4652596A (en) | 1995-01-09 | 1996-07-31 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
US20030158369A1 (en) | 1995-02-02 | 2003-08-21 | Slagel Edwin C. | Impact resistant polyurethane and method of manufacture thereof |
GB9506946D0 (en) | 1995-04-04 | 1995-05-24 | Univ Strathclyde | Microgels |
ES2231816T3 (es) | 1995-05-26 | 2005-05-16 | Henkel Kommanditgesellschaft Auf Aktien | Procedimiento de pegado. |
DK0828495T3 (da) | 1995-06-01 | 2003-02-24 | Searle & Co | Misoprostolholdige faste stabiliserede dispersioner |
US5747058A (en) * | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US7833543B2 (en) * | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5733538A (en) | 1995-06-07 | 1998-03-31 | Thoratec Laboratories, Inc. | Surface-modifying copolymers having cell adhesion properties |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US5900433A (en) | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
US5948416A (en) | 1995-06-29 | 1999-09-07 | The Procter & Gamble Company | Stable topical compositions |
US6201065B1 (en) | 1995-07-28 | 2001-03-13 | Focal, Inc. | Multiblock biodegradable hydrogels for drug delivery and tissue treatment |
KR19990044445A (ko) | 1995-09-13 | 1999-06-25 | 니뽄 신야쿠 가부시키가이샤 | Pge1 함유 동결건조 제제 및 그 제법 |
DE19541326A1 (de) | 1995-11-06 | 1997-05-07 | Basf Ag | Wasserlösliche oder wasserdispergierbare Polyurethane mit endständigen Säuregruppen, ihre Herstellung und ihre Verwendung |
DE19541658A1 (de) | 1995-11-08 | 1997-05-15 | Basf Ag | Wasserlösliche oder wasserdispergierbare Pfropfpolymere, ihre Herstellung und ihre Verwendung |
US6008312A (en) | 1995-12-01 | 1999-12-28 | Hokushin Corp | Method for producing millable polyurethanes and polyurethane elastomers |
US6103852A (en) | 1995-12-01 | 2000-08-15 | Hokushin Corporation | Method for preparing amorphous polymer chains in elastomers |
KR100459029B1 (ko) | 1995-12-27 | 2006-03-27 | 얀센 파마슈티카 엔.브이. | 생점착성고체투여형 |
US6521164B1 (en) | 1996-02-06 | 2003-02-18 | Parker-Hannifin Corporation | Injection-moldable thermoplastic polyurethane elastomer |
US5627254A (en) | 1996-05-03 | 1997-05-06 | The Dow Chemical Company | Rigid thermoplastic plyurethane comprising units of butane diol and a polyethylene glycol |
US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
BR9706561A (pt) | 1996-07-01 | 1999-07-20 | Basf Corp | Composições curáveis para revestimento contendo aditivos de carbamato |
US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
US5993972A (en) | 1996-08-26 | 1999-11-30 | Tyndale Plains-Hunter, Ltd. | Hydrophilic and hydrophobic polyether polyurethanes and uses therefor |
US6184248B1 (en) | 1996-09-05 | 2001-02-06 | Robert K. K. Lee | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6043224A (en) | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
US6130309A (en) | 1996-09-20 | 2000-10-10 | Tyndale Plains-Hunter, Ltd. | Hydrophilic polyether polyurethanes containing carboxylic acid |
TR199900970T2 (en) | 1996-11-04 | 1999-07-21 | Imperial Chemical Industries Plc | B�k�lmez poli�retan k�p�kleri. |
WO1998027962A2 (en) | 1996-12-20 | 1998-07-02 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
US5853767A (en) | 1997-01-02 | 1998-12-29 | Melman; Steven A. | Compositions for treating fungal, parasitic and/or bacterial infections, especially infections of organs such as the skin and vagina |
US20050208152A1 (en) | 1997-01-22 | 2005-09-22 | Marton Milankovits | Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications |
WO1998044952A1 (en) | 1997-04-04 | 1998-10-15 | Monsanto Company | pH-SELECTIVE DELIVERY SYSTEM USING CROSS-LINKED POLYMERIC RESINS AS VEHICLES |
US20020115814A1 (en) | 1997-04-28 | 2002-08-22 | Woodhouse Kimberly Ann | Incorporation by reference of co-pending application |
US6221997B1 (en) | 1997-04-28 | 2001-04-24 | Kimberly Ann Woodhouse | Biodegradable polyurethanes |
GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
JPH10332902A (ja) | 1997-05-27 | 1998-12-18 | Nippon Ee R C Kk | プラスチックレンズとその製造方法及びプライマー組成物 |
US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
ES2123466B1 (es) | 1997-06-11 | 1999-11-16 | Merquinsa Mercados Quimicos S | Termoplastico de poliuretano y procedimiento para su obtencion. |
US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US6197327B1 (en) | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US6039968A (en) * | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
KR20010021625A (ko) | 1997-07-09 | 2001-03-15 | 추후보정 | 개선된 남성발기 기능장애 치료방법 및 그 조성물 |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
JP3130273B2 (ja) | 1997-08-05 | 2001-01-31 | 三菱樹脂株式会社 | 雨どい |
CA2301650A1 (en) * | 1997-08-25 | 1999-03-04 | Union Carbide Chemicals & Plastics Technology Corporation | Biodegradable lactone copolymers |
DE19737348C2 (de) | 1997-08-27 | 2002-07-25 | Dan-Gabriel Vulpescu | Neue Clindamycin und Clotrimazol enthaltende pharmazeutische Zusammensetzung |
US6630050B1 (en) * | 1997-09-24 | 2003-10-07 | Henkel Kommanditgesellschaft Auf Aktien | Polyurethane adhesive |
DE19742217A1 (de) | 1997-09-24 | 1999-04-01 | Henkel Kgaa | Hydrophiles, hochmolekulares Polyurethan, Klebstoffzusammensetzungen, die dieses enthalten sowie Verwendung dieses Polyurethans |
DE19744473A1 (de) | 1997-10-09 | 1999-04-15 | Basf Ag | Verwendung von wasserlöslichen oder wasserdispergierbaren Polyurethanen als Überzugsmittel oder Bindemittel für pharmazeutische Darreichungsformen |
US20020004529A1 (en) | 1997-10-20 | 2002-01-10 | Gary W. Neal | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US20050070516A1 (en) | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
CA2306837C (en) | 1997-10-28 | 2007-05-08 | Asivi, Llc. | Treatment of female sexual dysfunction |
US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US6414028B1 (en) | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
US6046244A (en) | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
CA2310093C (en) | 1997-11-17 | 2008-10-28 | Cosma International Inc. | Projection welded panel spacer and method of making the same |
ES2138918B1 (es) | 1997-11-20 | 2000-09-16 | Merquinsa Mercados Quimicos S | Termoplastico de poliuretano cristalino y metodo para su obtencion. |
US20020031513A1 (en) | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
GB2331924A (en) | 1997-12-08 | 1999-06-09 | Phares Pharm Res Nv | Lipid compositions and their use |
US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
US5959775A (en) | 1997-12-23 | 1999-09-28 | 3M Innovative Properties Company | Urethane/acrylate bead bond for retroreflective articles |
DE19757569A1 (de) | 1997-12-23 | 1999-06-24 | Bayer Ag | Aliphatische, emissionsarme, sinterfähige thermoplastische Polyurethanformmassen |
DE69926730T2 (de) * | 1998-01-28 | 2006-06-08 | Bristol-Myers Squibb Co. | Verfahren zur Herstellung von Polyurethanklebstoffen und dadurch hergestellte Klebstoffe |
US6028057A (en) * | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
BRPI9908893B8 (pt) | 1998-03-19 | 2021-05-25 | Merck & Co Inc | composição polimérica líquida para a liberação controlada de substâncias bioativas hidrofóbicas. |
US6423345B2 (en) | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
US6031002A (en) | 1998-05-01 | 2000-02-29 | Michael Ebert | Method for enhancing female sexual response and a composition therefor |
US5891915A (en) | 1998-05-01 | 1999-04-06 | Wysor; Michael S. | Method for enhancing female sexual response and an ointment therefor |
US6013637A (en) | 1998-06-12 | 2000-01-11 | Dermik Laboratories Inc. | Anti-acne method and composition |
US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
IL140268A0 (en) | 1998-06-30 | 2002-02-10 | Amgen Inc | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
DE19847791A1 (de) | 1998-10-16 | 2000-04-20 | Bayer Ag | Wäßrige Polyurethandispersionen |
NL1010367C2 (nl) | 1998-10-21 | 2000-04-25 | Akzo Nobel Nv | Waterdampdoorlatende thermoplastische polyurethaanfilm. |
DE19849499A1 (de) | 1998-10-27 | 2000-05-04 | Basf Ag | Verfahren zur vollständigen Trocknung von Hydrogelen |
GB9826192D0 (en) | 1998-12-01 | 1999-01-20 | Controlled Theraputics Scotlan | Oral transmucosal delivery |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US20050004226A1 (en) | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
DE19900457A1 (de) | 1999-01-08 | 2000-07-13 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
DE10004723A1 (de) | 2000-02-03 | 2001-08-09 | Bayer Ag | Wässrige Sperrschicht auf Basis von Polyurethan-Disperionen |
US6545119B2 (en) | 1999-03-08 | 2003-04-08 | Toyo Boseki Kabushiki Kaisha | Magnetic recording media and thermoplastic polyurethane resins therefor |
ES2244422T3 (es) | 1999-04-01 | 2005-12-16 | Alza Corporation | Dispositivos para la administracion transdermica de farmacos que comprenden un deposito de poliuretano para farmacos. |
DE19915932A1 (de) | 1999-04-09 | 2000-10-19 | Freudenberg Carl Fa | Thermoplastisch verarbeitbare Polyurethan-Formmasse |
US6592472B2 (en) | 1999-04-20 | 2003-07-15 | Callaway Golf Company | Golf ball having a non-yellowing cover |
US6607686B2 (en) | 1999-04-20 | 2003-08-19 | Callaway Golf Company | Thermosetting polyurethane material for a golf ball |
US6117024A (en) | 1999-04-20 | 2000-09-12 | Callaway Golf Company | Golf ball with polyurethane cover |
IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
TWI232111B (en) | 1999-08-06 | 2005-05-11 | Upjohn Co | Intravaginal clindamycin ovule composition |
US6642274B1 (en) | 1999-09-09 | 2003-11-04 | Gary W. Neal | Methods and compositions for preventing and treating prostate disorders |
US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US6693135B2 (en) | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US7105571B2 (en) | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
US20040110843A1 (en) | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
IT1317735B1 (it) | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
DE10028810A1 (de) | 2000-06-10 | 2001-12-20 | Henkel Kgaa | Polyurethan-Zusammensetzungen auf der Basis von Polyester-Block-Copolymeren |
US6803495B2 (en) | 2000-06-28 | 2004-10-12 | World Properties, Inc. | Polyurethane foam composition and method of manufacture thereof |
US20040047910A1 (en) * | 2000-07-07 | 2004-03-11 | Christian Beckett | Suppository and composition comprising at least one polyethylene glycol |
DE10050137A1 (de) | 2000-10-11 | 2002-04-18 | Bayer Ag | Stabilisierte Mono- und Polyasparaginsäureester |
DE10051392A1 (de) | 2000-10-17 | 2002-04-18 | Bayer Ag | Elektroisolierlackbindemittel mit Harnstoff- und/oder Hydantoinstruktur |
JP5027962B2 (ja) | 2000-10-19 | 2012-09-19 | Dic株式会社 | 液状ウレタンプレポリマーの製造方法および樹脂組成物 |
US6811549B2 (en) | 2001-02-16 | 2004-11-02 | William H. Fleming | Administration of therapeutic or diagnostic agents using interlabial pad |
DE10112366B4 (de) | 2001-03-15 | 2006-06-08 | Bayer Materialscience Ag | Aliphatische thermoplastische Polyurethane und ihre Verwendung |
US6881788B2 (en) | 2001-08-21 | 2005-04-19 | Mitsui Takeda Chemicals, Inc. | Polyurethane resin water dispersion and aqueous polyurethane adhesive |
AU2003207961A1 (en) | 2002-01-16 | 2003-07-30 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
CH697081A5 (de) | 2002-01-22 | 2008-04-30 | Andreas F Dr Schaub | Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten. |
NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
WO2003065924A1 (en) * | 2002-02-08 | 2003-08-14 | Advanced Animal Technology Limited | Control of a biological function |
US6861503B2 (en) * | 2002-02-27 | 2005-03-01 | Poly-Med, Inc. | Interlinked solid polyethylene glycols and copolymers thereof |
US7358295B2 (en) | 2002-04-05 | 2008-04-15 | Lubrizol Advanced Materials, Inc. | Hybrid polymer composition, and article therefrom |
US6897281B2 (en) | 2002-04-05 | 2005-05-24 | Noveon Ip Holdings Corp. | Breathable polyurethanes, blends, and articles |
US7179481B2 (en) * | 2002-09-19 | 2007-02-20 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
EP1556428B1 (en) | 2002-10-28 | 2014-06-11 | Covidien LP | Fast curing compositions |
US20040142847A1 (en) | 2002-11-21 | 2004-07-22 | Rolf Bayersdoerfer | Detergent tablets with polyurethane coating |
US20050181030A1 (en) | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
US6841574B2 (en) | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
WO2004065450A2 (en) | 2003-01-16 | 2004-08-05 | Carnegie Mellon University | Biodegradable polyurethanes and use thereof |
GB0301577D0 (en) | 2003-01-23 | 2003-02-26 | Edko Pazarlama Tanitim Ltd Sti | Topical pharmaceutical and/or cosmetic dispense systems |
CN1292038C (zh) * | 2003-03-14 | 2006-12-27 | 天津大学 | 亲水性聚氨酯压敏胶及其制备方法 |
GB0306977D0 (en) | 2003-03-26 | 2003-04-30 | Metris Therapeutics Ltd | Device |
WO2004091579A1 (en) * | 2003-04-16 | 2004-10-28 | Pharmacia Corporation | Stabilized prostaglandin formulation |
ATE461681T1 (de) | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
JP2005002691A (ja) | 2003-06-13 | 2005-01-06 | Nippon Yusoki Co Ltd | 埋設用磁気マーカー、その製造方法、及び車両誘導設備 |
US8404272B2 (en) | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
US8399013B2 (en) * | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
CA2531640C (en) * | 2003-07-10 | 2013-06-18 | Galen (Chemicals) Limited | Intravaginal drug delivery devices |
WO2005013906A2 (en) | 2003-08-08 | 2005-02-17 | Sri International | pH-RESPONSIVE FILM FOR INTRAVAGINAL DELIVERY OF A BENEFICIAL AGENT |
EP1667619A4 (en) | 2003-09-19 | 2007-10-10 | Drugtech Corp | PHARMACEUTICAL FEEDING SYSTEM |
DE50300325D1 (de) | 2003-11-03 | 2005-03-31 | Peter-Hansen Volkmann | Vaginalpflegezusammensetzung |
ES2235654B1 (es) | 2003-12-26 | 2006-08-01 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) | Metodo de induccion y sincronizacion de la ovulacion para la inseminacion artificial sistematica en ganado caprino. |
EP1555278A1 (en) * | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
US6994078B2 (en) * | 2004-01-28 | 2006-02-07 | New Condensator, Inc. | Apparatus for removing contaminants from crankcase emissions |
US20050169975A1 (en) | 2004-02-03 | 2005-08-04 | Nitto Denko Corporation | Film base material for adhesive skin patch and adhesive skin patch |
DE102004008015A1 (de) | 2004-02-19 | 2005-09-08 | Cognis Deutschland Gmbh & Co. Kg | Verdickungsmittel für Polyurethanbasis |
MY146259A (en) | 2004-03-24 | 2012-07-31 | Polynovo Biomaterials Pty Ltd | Boidegradable polyurethane and polyurethane ureas |
US20070166382A1 (en) * | 2004-03-26 | 2007-07-19 | Kiser Patrick F | Bioresponsive polymer system for delivery of microbicides |
WO2005092404A1 (ja) | 2004-03-29 | 2005-10-06 | Sanyo Chemical Industries, Ltd. | 医療用接着剤 |
US20080140185A1 (en) | 2004-04-15 | 2008-06-12 | University Of Utah Research Foundation | Biodegradable and Biocompatible Peg-Based Poly(Ester-Urethanes) |
US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US20060003950A1 (en) | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
DE102004031786A1 (de) | 2004-07-01 | 2006-01-26 | Cognis Deutschland Gmbh & Co. Kg | Verdickungsmittel auf Polyurethanbasis |
DK1768625T3 (da) * | 2004-07-09 | 2011-05-09 | Population Council Inc | Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer |
US8460378B2 (en) | 2004-07-26 | 2013-06-11 | DePuy Sythes Products, LLC | Biocompatible, biodegradable polyurethane materials with controlled hydrophobic to hydrophilic ratio |
GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
WO2006024138A1 (en) | 2004-08-30 | 2006-03-09 | Taro Pharmaceutical Industries Ltd. | A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
US20060093675A1 (en) | 2004-10-29 | 2006-05-04 | Mathew Ebmeier | Intravaginal treatment of vaginal infections with metronidazole compositions |
GB0424526D0 (en) | 2004-11-05 | 2004-12-08 | Controlled Therapeutics Sct | Hydrogel delivery vehicle |
CA2601773A1 (en) * | 2005-02-03 | 2006-08-10 | Duramed Pharmaceuticals, Inc. | Compositions of unconjugated estrogens and methods for their use |
WO2006089561A1 (en) | 2005-02-23 | 2006-08-31 | Abbas Abdelsalam Ghazi | Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix. |
US7795467B1 (en) | 2005-04-26 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyurethanes for use in medical devices |
TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
ATE495752T1 (de) * | 2005-07-19 | 2011-02-15 | Population Council Inc | Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten |
JP2009518129A (ja) * | 2005-12-06 | 2009-05-07 | タイコ ヘルスケア グループ リミテッド パートナーシップ | 生体吸収性外科用組成物 |
WO2007067806A2 (en) * | 2005-12-08 | 2007-06-14 | Tyco Healthcare Group Lp | Biocompatible surgical compositons |
US20070148105A1 (en) | 2005-12-22 | 2007-06-28 | Donald Spector | Compositions and methods comprising magnetic particles for health use |
US20090061172A1 (en) | 2006-01-26 | 2009-03-05 | Komatsu Seiren Co., Ltd. | Polyurethane Resin Composition for Durable Moisture-Permeable Waterproof Sheet, Moisture-Permeable Waterproof Sheet and Method of Manufacturing the Same |
WO2007101808A1 (de) | 2006-03-06 | 2007-09-13 | Basf Se | Vliesstoff auf der basis von thermoplastischem polyurethan |
EP2012803A4 (en) | 2006-04-20 | 2012-08-01 | Univ Utah Res Found | POLYMER COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF |
GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
US7717892B2 (en) * | 2006-07-10 | 2010-05-18 | Mcneil-Ppc, Inc. | Method of treating urinary incontinence |
AU2007274081B2 (en) | 2006-07-12 | 2012-08-02 | Controlled Therapeutics (Scotland) Ltd. | Drug delivery polymer with hydrochloride salt of clindamycin |
US8138220B2 (en) | 2006-09-28 | 2012-03-20 | H. Lundbeck A/S | [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
CA2670157A1 (en) * | 2006-11-22 | 2008-05-29 | N.V. Organon | Delivery system for risperidone |
US7781651B2 (en) | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV715590 |
ES2696999T3 (es) * | 2007-06-26 | 2019-01-21 | Allergan Pharmaceuticals Int Ltd | Dispositivos de administración intravaginal de medicamentos para la administración de macromoléculas y medicamentos solubles en agua |
US20110059040A1 (en) * | 2007-06-27 | 2011-03-10 | Kiser Patrick F | Compositions and methods for inhibiting viral and bacterial activity |
AR066166A1 (es) * | 2007-09-21 | 2009-07-29 | Organon Nv | Sistema de suministro de droga |
US9426414B2 (en) | 2007-12-10 | 2016-08-23 | Qualcomm Incorporated | Reference selection for video interpolation or extrapolation |
KR20100120665A (ko) * | 2008-01-25 | 2010-11-16 | 더 유니버시티 오브 유타 리서치 파운데이션 | 일차 방출 중합체 |
FI20085277A0 (fi) * | 2008-04-02 | 2008-04-02 | Bayer Schering Pharma Oy | Kohdunsisäinen järjestelmä |
US20090269480A1 (en) | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents |
WO2010036878A1 (en) | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
WO2010035837A1 (ja) | 2008-09-29 | 2010-04-01 | 三菱化学株式会社 | コハク酸およびその製造方法 |
PL2419108T3 (pl) | 2009-04-14 | 2017-08-31 | Laboratoire Hra Pharma | Sposób antykoncepcji na żądanie |
EP2456421B1 (en) | 2009-07-21 | 2017-04-05 | The Population Council, Inc. | Multi-layered gradient vaginal ring |
FI123146B (fi) | 2009-10-01 | 2012-11-30 | Bayer Schering Pharma Oy | Kohdunsisäinen järjestelmä |
US20110150955A1 (en) * | 2009-12-23 | 2011-06-23 | Shannon Elizabeth Klingman | Products and Methods for Reducing Malodor from the Pudendum |
-
2006
- 2006-07-05 GB GBGB0613333.4A patent/GB0613333D0/en not_active Ceased
-
2007
- 2007-06-27 WO PCT/GB2007/002401 patent/WO2008003932A1/en active Application Filing
- 2007-06-27 PL PL15178709T patent/PL2966104T3/pl unknown
- 2007-06-27 JP JP2009517393A patent/JP5394237B2/ja active Active
- 2007-06-27 CN CN2007800254415A patent/CN101484493B/zh active Active
- 2007-06-27 ES ES15178709T patent/ES2707749T3/es active Active
- 2007-06-27 CA CA2656489A patent/CA2656489C/en active Active
- 2007-06-27 ES ES07733393.8T patent/ES2564419T3/es active Active
- 2007-06-27 US US12/307,514 patent/US8974813B2/en active Active
- 2007-06-27 AU AU2007271000A patent/AU2007271000B2/en active Active
- 2007-06-27 BR BRPI0713630-7A patent/BRPI0713630B1/pt active IP Right Grant
- 2007-06-27 TR TR2019/00597T patent/TR201900597T4/tr unknown
- 2007-06-27 EP EP15178709.0A patent/EP2966104B1/en active Active
- 2007-06-27 EP EP07733393.8A patent/EP2035476B1/en active Active
-
2015
- 2015-02-06 US US14/616,314 patent/US10105445B2/en active Active
-
2016
- 2016-07-12 HK HK16108127.1A patent/HK1220220A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753663A (ja) * | 1993-07-30 | 1995-02-28 | Takiron Co Ltd | 経皮吸収製剤用基剤ポリマー |
JPH09157409A (ja) * | 1995-12-01 | 1997-06-17 | Nippon Miractran Kk | 透湿フィルム又はシート、及びその製造方法 |
JP2001501232A (ja) * | 1996-09-20 | 2001-01-30 | バイエル・アクチエンゲゼルシヤフト | 活性物質含有の熱可塑性ポリウレタン |
JP2002088571A (ja) * | 2000-09-11 | 2002-03-27 | Du Pont Toray Co Ltd | ポリウレタン繊維の製造方法 |
JP2002361053A (ja) * | 2001-06-12 | 2002-12-17 | Nisshinbo Ind Inc | 分離膜モジュールの洗浄用ゲル粒子、製法及び洗浄方法 |
JP2006500456A (ja) * | 2002-09-27 | 2006-01-05 | コントロールド・セラピューティクス(スコットランド)・リミテッド | 水膨潤性ポリマー |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019111839A1 (ja) * | 2017-12-04 | 2019-06-13 | 住友精化株式会社 | 揮発性物質放散用組成物 |
CN111212883A (zh) * | 2017-12-04 | 2020-05-29 | 住友精化株式会社 | 挥发性物质发散用组合物 |
JPWO2019111839A1 (ja) * | 2017-12-04 | 2021-01-07 | 住友精化株式会社 | 揮発性物質放散用組成物 |
JP7185641B2 (ja) | 2017-12-04 | 2022-12-07 | 住友精化株式会社 | 揮発性物質放散用組成物 |
CN111212883B (zh) * | 2017-12-04 | 2023-08-15 | 住友精化株式会社 | 挥发性物质发散用组合物 |
JP2022500394A (ja) * | 2018-09-17 | 2022-01-04 | ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. | ポリウレタン賦形剤 |
JP7387960B2 (ja) | 2018-09-17 | 2023-11-29 | ディーエスエム アイピー アセッツ ビー.ブイ. | ポリウレタン賦形剤 |
Also Published As
Publication number | Publication date |
---|---|
ES2564419T3 (es) | 2016-03-22 |
EP2035476A1 (en) | 2009-03-18 |
BRPI0713630B1 (pt) | 2018-03-20 |
BRPI0713630A2 (pt) | 2012-10-30 |
HK1220220A1 (zh) | 2017-04-28 |
CA2656489C (en) | 2016-01-26 |
CN101484493B (zh) | 2012-03-28 |
EP2035476B1 (en) | 2016-01-13 |
PL2966104T3 (pl) | 2019-04-30 |
JP5394237B2 (ja) | 2014-01-22 |
CN101484493A (zh) | 2009-07-15 |
TR201900597T4 (tr) | 2019-02-21 |
US10105445B2 (en) | 2018-10-23 |
AU2007271000A1 (en) | 2008-01-10 |
AU2007271000B2 (en) | 2013-01-31 |
EP2966104A1 (en) | 2016-01-13 |
WO2008003932A1 (en) | 2008-01-10 |
US8974813B2 (en) | 2015-03-10 |
US20150165044A1 (en) | 2015-06-18 |
CA2656489A1 (en) | 2008-01-10 |
ES2707749T3 (es) | 2019-04-04 |
GB0613333D0 (en) | 2006-08-16 |
US20090291120A1 (en) | 2009-11-26 |
EP2966104B1 (en) | 2018-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5394237B2 (ja) | 親水性ポリウレタン化合物 | |
JP5307710B2 (ja) | ポリウレタンエラストマー | |
JP4612419B2 (ja) | 水膨潤性ポリマー | |
EP3017809A1 (en) | Drug-device unit containing quinagolide | |
AU2013205539B2 (en) | Polyurethane elastomers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100621 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100621 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121219 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131008 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131016 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5394237 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |